ARS Pharmaceuticals (SPRY) Non-Current Assets (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Non-Current Assets of $42.3 million for Q1 2026, down 0.98% sequentially from $42.8 million in Q4 2025, and up 80.47% YoY from $23.5 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Non-Current Assets (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Non-Current Assets for 7 years, with the latest figure at $42.3 million in Q1 2026.
- Quarterly Non-Current Assets rose 80.47% year-over-year to $42.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $151.1 million (up 200.0% YoY) and the FY2025 annual result came in at $42.8 million, up 153.62% from the prior year.
- Non-Current Assets eased to $42.3 million in Q1 2026 per SPRY's latest filing, from $42.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $51.1 million in Q1 2022 and troughed at $265000.0 in Q3 2022.
- A 5-year average of $17.8 million and a median of $8.8 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets sank 99.44% in 2022, then soared 2508.79% in 2025.
- Over 5 years, Non-Current Assets stood at $3.7 million in 2022, then sank by 60.86% to $1.5 million in 2023, then surged by 1053.08% to $16.9 million in 2024, then surged by 153.62% to $42.8 million in 2025, then dropped by 0.98% to $42.3 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $42.3 million, $42.8 million, and $33.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 37.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.99 Mn |
| Mar 31, 2026 | 42.34 Mn |
| Dec 31, 2025 | 42.76 Mn |
| Sep 30, 2025 | 33.94 Mn |
| Jun 30, 2025 | 32.04 Mn |
| Mar 31, 2025 | 23.46 Mn |
| Dec 31, 2024 | 16.86 Mn |
| Sep 30, 2024 | 8.81 Mn |
| Jun 30, 2024 | 1.23 Mn |
| Mar 31, 2024 | 1.34 Mn |
| Dec 31, 2023 | 1.46 Mn |
| Sep 30, 2023 | 4.09 Mn |
| Jun 30, 2023 | 3.72 Mn |
| Mar 31, 2023 | 3.84 Mn |
| Dec 31, 2022 | 3.74 Mn |
| Sep 30, 2022 | 265,000.00 |
| Jun 30, 2022 | 30.87 Mn |
| Mar 31, 2022 | 51.14 Mn |
| Dec 31, 2021 | 716,000.00 |
| Sep 30, 2021 | 47.21 Mn |